SORRENTO THERAPEUTICS WKN: A1W8DY ISIN: US83587F2020 Kürzel: SRNE Forum: Aktien Thema: Hauptdiskussion
Sorrento Therapeutics, Inc. (NASDAQ:SRNE) is a San Diego, California-based biotech company developing treatments for cancer, intractable pain, and COVID-19. The company has eight manufacturing sites, five in the US and three in China. ADVERTISEMENT In a research note issued to investors on November 2, Brandon Folkes at Cantor Fitzgerald started coverage on Sorrento Therapeutics, Inc. (NASDAQ:SRNE) with a target price of $5 and assigned the stock an Overweight rating. The target price reflects a handsome upside potential of 284% from the closing price as of December 7. In August, the drug candidate SP-103 from Scilex, Sorrento Therapeutics, Inc.'s (NASDAQ:SRNE) majority-owned subsidiary, was given fast-track status by the U.S. Food and Drug Administration (FDA). The drug is targeted toward the treatment of severe low back pain (LBP). Folkes believes that Sorrento Therapeutics, Inc. (NASDAQ:SRNE) has the ability to develop multiple best-in-class products in high-value fields of oncology, non-opioid pain relief, and infectious diseases like COVID-19. Experts think Sorrento Therapeutics, Inc. (NASDAQ:SRNE) is trading at a significant valuation discount compared to its rivals, making it one of the best small-cap stocks to invest in.
Sorrento Therapeutics, Inc. (NASDAQ:SRNE) is a San Diego, California-based biotech company developing treatments for cancer, intractable pain, and COVID-19. The company has eight manufacturing sites, five in the US and three in China. ADVERTISEMENT In a research note issued to investors on November 2, Brandon Folkes at Cantor Fitzgerald started coverage on Sorrento Therapeutics, Inc. (NASDAQ:SRNE) with a target price of $5 and assigned the stock an Overweight rating. The target price reflects a handsome upside potential of 284% from the closing price as of December 7. In August, the drug candidate SP-103 from Scilex, Sorrento Therapeutics, Inc.'s (NASDAQ:SRNE) majority-owned subsidiary, was given fast-track status by the U.S. Food and Drug Administration (FDA). The drug is targeted toward the treatment of severe low back pain (LBP). Folkes believes that Sorrento Therapeutics, Inc. (NASDAQ:SRNE) has the ability to develop multiple best-in-class products in high-value fields of oncology, non-opioid pain relief, and infectious diseases like COVID-19. Experts think Sorrento Therapeutics, Inc. (NASDAQ:SRNE) is trading at a significant valuation discount compared to its rivals, making it one of the best small-cap stocks to invest in.
Mehr zu diesem Wert
|
Thema | ||
---|---|---|---|
1 | SORRENTO THERAPEUTICS Hauptdiskussion | ||
2 | SORRENTO INFORMATIV | ||
3 | Sorrento, Spam frei!! | ||
4 | Ausschließlich Sorrento News | ||
5 | Never Surrender ✌️ |
|
Thema | ||
---|---|---|---|
1 | Renk Group | -3,06 % | |
2 | NVIDIA Hauptdiskussion | +1,88 % | |
3 | VW Hauptdiskussion | -1,65 % | |
4 | MicroStrategy | -0,45 % | |
5 | DEUTZ Hauptdiskussion | -9,45 % | |
6 | XIAOMI CORP. CL.B Hauptdiskussion | -1,09 % | |
7 | Dax Prognose | -0,57 % | |
8 | Super Micro Computer Hauptdiskussion | -0,90 % | |
9 | für alle, die es ehrlich meinen beim Traden. | ||
10 | CARBIOS Hauptdiskussion | -11,27 % | Alle Diskussionen |
|
Thema | ||
---|---|---|---|
1 | Renk Group | -2,97 % | |
2 | NVIDIA Hauptdiskussion | +0,27 % | |
3 | VW Hauptdiskussion | -1,60 % | |
4 | MicroStrategy | -0,40 % | |
5 | DEUTZ Hauptdiskussion | -9,58 % | |
6 | XIAOMI CORP. CL.B Hauptdiskussion | -1,06 % | |
7 | Super Micro Computer Hauptdiskussion | -0,73 % | |
8 | CARBIOS Hauptdiskussion | -11,27 % | |
9 | DRONESHIELD LTD Hauptdiskussion | -3,22 % | |
10 | RENK (für normale, sachliche Kommunikation!) | -2,97 % | Alle Diskussionen |